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Background: The analysis of cancer incidence trends is essential to health care planning. The aim of this study is to
examine variations in cancer incidence rates in Lebanon between 2003 and 2008 and use the observed trends to
project cancer incidence until 2018.
Methods: Using secondary data with a cumulative caseload of 45,753 patients from the National Cancer Registry
database of the Ministry of Public Health in Lebanon, we estimated sex- and site- specific incidence of cancer for
each year of the six-year period between 2003 and 2008. Logarithmic regressions were fitted to estimate the cancer
incidence for the forecast years until 2018.
Results: Between 2003 and 2008, males and females presented with an overall 4.5% and 5.4% annual increase,
respectively. Significant increases were observed for cancers of the liver and prostate among males, and for cancers
of the liver, thyroid, and corpus uteri among females. By 2018, incidence rates were projected to approach 296.0
and 339.5 cases per 100,000 for males and females, respectively. The most common five types of cancer are
expected to be prostate, bladder, lung, non-Hodgkin, and colon among males; and breast, ovarian, non-Hodgkin,
lung, and colon among females.
Conclusion: The increased availability of screening programs and a growing smoking epidemic, most notably in
women, are the most likely explanations behind the increased cancer incidence in the past decade. An aging
population and higher proportion of older people suggest further increases in the cancer caseload in the future.
The health care system in Lebanon will be required to adapt to the growing burden of cancer in our population.
Keywords: Cancer, Lebanon, Surveillance, Trend analysisCancer is the second leading cause of death after heart
disease and stroke. Cancer also exerts the highest social
and economic burden of all causes of morbidity through
cost of diagnosis and treatment, and years of life lost
due to disability [1]. Lebanon, a small middle-income
country on the Eastern Mediterranean shore, is at the
third stage of its demographic transition characterized* Correspondence: as04@aub.edu.lb; am00@aub.edu.lb
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distribution, and reproduction in any mediumby a decline in both fertility and mortality rates [2]. The
United Nations estimates that the average life expect-
ancy in Lebanon will rise from 71 to 78.7 years between
2009 and 2050, leading to an increase in the median
population age from 28.8 to 41.7 years as well as the per-
centage of older population aged 60 years and above
from 10.3% to 25.8% [3]. With an aging population, it is
expected that cancer burden will increase and its associ-
ated economic toll will rise dramatically. The only study
that examined cancer incidence at the national level
dates back to 1998 and was based on data collated by
the Lebanese Cancer Epidemiology Group (LCEG) [4].
In spite of the inherent limitations and challenges of the
initial efforts, the study served as the first step toward aentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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National Cancer Registry in the country. Later on, sev-
eral attempts at examining major sites of cancer in
Lebanon and their epidemiological profile were made,
but these have relied primarily on hospital-based tumor
registries and hence were of limited generalizability. The
present study examines variations in cancer incidence
rates in Lebanon over a six-year period from 2003 to
2008 and uses observed trends to project cancer inci-
dence until 2018. Findings from this study are crucial to
anticipate future national health needs and develop ac-
cordingly strategies for disease prevention and control.
Materials and methods
Six-year trend analysis from 2003 until 2008
The six consecutive years from 2003 until 2008 were
drawn from published data as provided by the Lebanese
National Cancer Registry database [5]. Using the Join-
point Regression Program (JRP), sex-specific and age-
standardized incidence rates for each year of study and
each primary cancer site were calculated for the study
period (2003–2008). Rates were standardized according
to the World Standard Population.
The annual percent change (APC) in incidence rate
was also calculated. The APC is based on the assump-
tion that cancer rates change at a constant percentage of
the previous year’s rate [6]. It allows comparing trends
among scales for both rare and common diseases since
it relies on percentages rather than increments. The cri-
teria for characterizing the observed trends followed the
NCI guidelines [7]: if the APC >0.5% with statistical sig-
nificance, then the trend is judged to be rising; if the
APC < −0.5% with statistical significance, then the trend
is judged to be falling; if the −0.5% ≤APC ≤ 0.5% with no
statistical significance, then the trend is judged to be
stable; and if the APC < −0.5 or APC >0.5 with no statis-
tical significance, then the trend is judged to be a non-
significant change (rise/fall). All the data that we analyzed
were stratified by sex and presented as age-standardized
rates (ASR). Statistical significance was also defined here
at p-value ≤0.05.
Trend variations between the sexes were compared using
two tests, parallelism and coincidence. Parallelism examines
whether the regression mean functions (i.e., slope of the
change in trend) are similar in direction between males
and females, while coincidence indicates whether the re-
gression mean functions are identical (i.e., similar overall
incidence) between males and females [8].
Ten-year projected estimates from 2009 until 2018
Projections of the cancer incidence in Lebanon for the
year 2018 were estimated using historical data covering
the six-year period (2003–2008). The age-standardized
rates from this period, the dependent variable, were fittedinto a logarithmic model and the year(s) variable extend-
ing to 2018 as the independent variable in the model. The
resulting rates from this model followed a logarithmic
function over the study period. The logarithmic model
was found to be best fitting and the most biologically rea-
sonable model to describe the cancer incidence over time.
Linear and log-linear regression models have been found
to be the most practical means by which future patterns
of cancer incidence can be estimated for periods of up to
10 to 15 years assuming no change in underlying trends
[9]. These models assume a Poisson distribution for the
observed number of incident cases, as predictions gener-
ated in this way are more reliable than those based on an
assumption of normal distribution [10].
The fitted logarithmic model of the observed and im-
puted variables generated the new sex- and site-specific
cancer incidence coefficients. The R square, which mea-
sures how well the model explains the total variations,
and the p-value for the model were used to assess the
goodness-of-fit of the model, considering a p-value of
p ≤0.05 as significant.
Results
Incidence trends (2003–2008)
The cumulative caseloads for the study period (2003–
2008) included 45,753 patients, with males and females
providing nearly equal and stable contribution across
the years (48% and 52%, respectively). Table 1 provides
the age-standardized rates among males and females for
2003 and 2008 separately and shows the APC over the
six-year study period, which reflects the overall trend
across the years and not necessarily the difference be-
tween 2003 and 2008, as two points in time.
Top cancer sites
Among males, age-standardized incidence rates for pros-
tate cancer increased during the study period 2003–
2008 from 29.9 to 39.2 cases per 100,000 (Table 1) and
became the most-reported cancer site in 2008. This was
followed by bladder cancer (ASR = 34.0 per 100,000) and
lung cancer (ASR = 31.8 per 100,000), ranking second
and third, respectively. Colon incidence rates ranked
fourth and remained stable at 15.3 per 100,000 while
non-Hodgkin lymphoma rates increased from 9.7 to 14.1
per 100,000 and became the fifth most-reported cancer
site in 2008.
Among females, breast cancer remained the most-
reported cancer site, with an increase in age-standardized
incidence rate from 78.3 in 2003 to 95.7 cases per 100,000
in 2008 (Table 1). Colon cancer was the second most-
common cancer at 14.1 cases per 100,000 despite a slight
decrease over the six-year period. The third most com-
mon cancer was lung, increasing slightly to 13.7 cases per
100,000 in 2008. Although non-Hodgkin lymphoma was
Table 1 Sex-stratified (average) annual percent change (APC) by cancer site, 2003 until 2008 (per 100,000)
Cancer site Parameter Comparison between genders
Males Females Parallelism Coincidence
2003 2008 APC Trend 2003 2008 APC Trend
Oropharyngeal 3.8 3.9 0.3% Stable 2.6 2.6 5.0% Rising 0.364 <0.001
Esophagus – 0.9 −4.9% Falling – 0.5 8.4% Rising <0.0011 0.061
Stomach 6.2 8.1 2.9% Rising 5.1 6.7 3.2% Rising 0.839 0.0342
Colon 14.1 15.3 0.7% Stable 13.1 14.1 −0.6% Falling 0.964 0.069
Rectum 4.1 4.2 −1.0% Falling 3.4 4.8 12.0% Rising 0.060 0.124
Liver 1.8 4.0 13.6% Rising* 1.5 3.9 18.3% Rising* 0.492 <0.0012
Gall bladder 1.8 1.2 −5.1% Falling 1.5 1.7 4.9% Rising 0.680 0.0352
Pancreas 3.4 4.7 6.0% Rising 2.9 2.7 −1.9% Falling 0.217 0.320
Larynx 5.6 5.7 3.3% Rising 1.3 1.6 3.6% Rising 0.999 0.0202
Lung 31.6 31.8 0.3% Stable 13.1 13.7 1.0% Rising 0.433 0.479
Bone 1.4 2.2 5.18% Rising 1.9 1.4 −3.0% Falling 0.302 0.093
Connective tissue 5.3 3.3 −11.0% Falling 2.8 2.7 −2.6% Falling 0.167 0.240
Melanoma of the skin 3.04 2.1 −12.6% Falling 1.5 1.9 −6.4% Falling 0.503 0.124
Prostate 29.9 39.2 7.6% Rising*
Testis and male genitalia 4.3 3.3 −6.3% Falling
Breast 78.3 95.7 5.4% Rising
Cervix uteri 4.9 5.6 1.8% Rising
Corpus uteri 5.3 9.0 11.4% Rising*
Ovary 1.1 9.4 7.2% Rising
Bladder 29.5 34.0 3.3% Rising 6.2 9.0 8.0% Rising 0.116 <0.0012
Kidney and urinary tract 3.8 5.6 9.34% Rising 2.2 2.4 1.0% Rising 0.216 0.0142
Brain and nervous system 5.9 6.7 2.8% Rising 3.3 5.0 5.2% Rising 0.869 0.080
Thyroid 1.6 3.6 19.1% Rising 4.2 8.2 12.7% Rising* 0.153 0.0202
Hodgkin disease 4.2 4.1 0.25% Rising 2.4 3.0 4.3% Rising 0.354 0.0342
Non-Hodgkin disease 9.7 14.1 4.2% Rising 7.5 11.6 5.9% Rising 0.340 <0.0012
All sites 191.3 225.7 4.5% Rising* 190.7 243.9 5.4% Rising* 0.292 0.0202
APC values that are significant are indicated with an asterisk (*).
1A p-value ≤0.05 on the parallelism test indicates that the trends (slopes) between males and females are significantly different.
2A p-value ≤0.05 on the coincidence test indicate that the difference in the rates (position of trend lines) between males and females are significantly different.
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in 2008 to the fourth most-reported malignancy. Ovarian
cancer ranked as the fifth most-common cancer in 2008
with 9.4 cases per 100,000.
Annual percent change (APC)
Among males, three out of the 21 considered cancer
sites showed a stable trend across the study period
(2003–2008), six showed a decreasing trend, and 12
showed an increasing trend, statistically significant in
the case of liver cancer and prostate cancer (APC of
13.6% and 7.6% respectively). Among females, out of the
23 considered sites, five sites showed a decreasing trend,
and 18 sites showed an increasing trend, statistically sig-
nificant for liver cancer, thyroid cancer, and corpus uteri
(APC of 18.3%, 12.7%, and 11.4%, respectively). Overall,males presented with a 4.5% (P < 0.05) annual increase
while females presented with 5.4% (P <0.05) annual in-
crease over the study period (Table 1).
Comparison of trends between genders
In contrast to males, females showed a steep annual
increase in esophageal cancer between 2003 and 2008
(P <0.001), but this resulted only in a marginal difference
on their trend coincidence (P <0.061). Cancers of the rec-
tum, gall bladder, pancreas, and bone had opposing trends
in the direction of change across gender, and this was
most notable for cancer of the rectum (P <0.06). For can-
cers of parallel direction of change, females had a signifi-
cantly higher annual trend change for cancers of the liver,
bladder and Hodgkin disease than males; while males had
a significantly higher annual trend change for cancers of
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(Table 1).
Projected cancer rates (2009–2018)
Table 2 presents the projected incidence rates for the
year 2018. Overall, cancer incidence rates in 2018 are
expected to approach 296.0 and 339.5 cases per 100,000
for males and females, respectively. The three most
common types of cancer in males in 2018 are expected
to be prostate, bladder, and lung, accounting for ap-
proximately half of all cancer cases. The most commonlyTable 2 Projected incidence rates for cancer of major
sites for the year 2018 (per 100,000)







Oropharyngeal 3.7 0.03 2.8 0.04
Esophagus 0.6 0.15 0.7 0.25
Stomach 9.3 0.21 7.7 0.08
Colon 17.1 0.26 10.9 0.03
Rectum 4.4 0.50 5.9 0.32
Liver 7.9 0.79* 6.6 0.62
Gall bladder 0.7 0.13 2.5 0.23
Pancreas 5.9 0.33 2.3 0.08
Larynx 7.9 0.26 2.0 0.29
Lung 32.7 0.04 14.3 0.07
Bone 3.8 0.19 1.1 0.15
Connective tissue 0.4 0.07 1.6 0.03
Melanoma
of the skin






Cervix uteri 5.8 0.09
Corpus uteri 16.0 0.91*
Ovary 22.0 0.49*
Bladder 41.2 0.29 13.4 0.64
Kidney and
urinary tract
9.4 0.65 2.2 0.02
Brain and
nervous system
7.1 0.08 1.6 0.18
Thyroid 7.0 0.72* 14.7 0.92*
Hodgkin disease 4.3 0.01 4.9 0.24
Non-Hodgkin
disease
22.1 0.34 20.0 0.39
All sites 296.0 0.67* 339.5 0.75*
R2(R-square) values that are significant with a p-value ≤0.05 are noted with an
asterisk (*), indicating a significantly fit model.diagnosed cancers in females in 2018 are expected to be
cancers of the breast, ovarian, and non-Hodgkin disease,
accounting for approximately half of all cancers. The R
squares show that the best-fitted models (R2 ≥ 0.8) for
males were for prostate (0.81), while the best-predicting
models in females were thyroid and corpus uteri (0.92
and 0.91, respectively).
Discussion
Early incidence rates for cancer in Lebanon were provided
by Abou-Daoud in 1966. Cancer rates were reported at
102.8 and 104.1 per 100,000 for males and females, re-
spectively [11]. The study observed high incidence of lung,
bronchus, and larynx cancer among males, while females
presented with high incidence of breast and cervix uteri
cancers. Thirty years later, a national study conducted by
the Lebanese Cancer Epidemiology Group in collaboration
with all hospitals, oncology specialists, and pathology cen-
ters in the country included a total of 4,388 incident cases
and reported national age-standardized incidence rates of
154.2 and 134.8 per 100,000 for males and females, re-
spectively [4]. For males, bladder cancer was the most
commonly reported cancer followed by cancers of the
prostate and the lung. For females, breast cancer remained
the most common cancer and accounted for one-third of
all reported cases. A national cancer registry was then
established under the auspices of the Ministry of Public
Health and published its first annual report on national
cancer incidence data in 2003, noting age-standardized
incidence rates of 191.3 and 190.7 per 100,000 for males
and females, respectively [5]. Bladder, prostate, and lung
cancers remained the highest-reported malignancies
among males. For females, breast cancer remained the
highest-reported cancer, followed by colon cancer and
non-Hodgkin lymphomas.
These major landmarks in the surveillance of cancer
in Lebanon show an increase in the incidence rates
across time and a change in the epidemiology of the dis-
ease. Figures 1, 2, 3 and 4 reproduce the data generated
from this study and present incidence rates for the five
most common cancers in males and females across the
years of the study (2003–2018). Cancers of prostate,
bladder, lung, colon, and non-Hodgkin were the most
common among males, and cancers of the breast, colon,
lung, non-Hodgkin, and ovary were the most common
among females. Currently, Lebanon includes the highest
proportion of older people in the Arab world (10% for
those aged 60 years and over) [2]. Whilst aging remains
the most compelling explanation for the rise in cancer
rates over the study period from 2009 until 2018, we
also note a disproportionate rise in smoking-related can-
cers represented by malignancies of the lungs, trachea,
and larynx. Females still lag behind males in the inci-
dence of such cancers, but they are following a similar
Figure 1 Cancer incidence of the five most common cancers in males (2003-2008).
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out as a cancer with an unusually high incidence, with a
pattern that exceeds other regional and international es-
timates [12].
Prostate cancer follows as the third most-reported
cancer in men. Prostate-related cases aggregate in those
65 years and above, showing an older age at diagnosis
[5]. The increased utilization of PSA screening may par-
tially account for some of this increasing trend; however,
projections indicate that this trend in prostate cancer is
expected to be maintained until 2018. Similarly, the high
occurrence of breast cancer among women may also be
related to increased use of mammographic screening
and early detection, an effort assisted by major aware-
ness campaigns that started in 2004.
Change in the contribution of all cancers
Between 2003 and 2008, females had a faster expansion
of the contribution of the most common cancer sites
compared to males. Between 2008 and 2018, this differ-
ential is reduced as the contribution of the common
cancer sites seems to expand at similar pace. We relateFigure 2 10-year cancer incidence projection of the five most commothis to differentials in the maturity of the cancer epidemic
between females and males. Males are approaching the
saturation of their risk factors and hence the incidence of
cancer cases, with the corresponding trend becoming
stable for lung cancer and decreasing for bladder cancer.
Females are increasingly being exposed to more risk fac-
tors than before, with maturation of the smoking epi-
demic and an increase in the incidence of smoking-related
cancers.
An increasing trend was observed in most of the cancer
sites in the period from 2003 to 2008 (Table 1). However,
a few cancers showed a non-significant decreasing trend
mainly in esophageal and melanoma of the skin. The rates
in these sites were initially low, which makes any variation
in these rates appear large when compared to the initial
estimates. The decrease in connective tissue cancer rate
was attributed to the adoption of a more specific classifi-
cation by topography than an actual decrease.
Change in the ranking of cancer sites
Among males, lung cancer was the most common can-
cer in 2003 with 31.6 cases per 100,000 cases. This wasn in males (2009-2018).
Figure 3 Cancer incidence of the five most common cancers in females (2003-2008).
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significant increases in prostate cancer made it to the
top of the list with 39.2 cases per 100,000 cases. Simi-
larly, bladder cancer rose to become the second most-
common reported cancer site among males with 34.0
cases per 100,000 cases, and lung cancer became the
third most-common type. Such a ranking is projected to
be maintained until 2018.
Between 2003 and 2008, the most notable changes in fe-
males were the rise in breast cancer incidence and the ap-
pearance of ovarian cancer as the fifth most commonly
reported cancer site. In 2018, breast cancer is projected to
remain the most-common reported cancer site, while
ovarian cancer is projected to increase and rank as the
second most-common reported site. This will be followedFigure 4 10-year cancer incidence projection of the five most commoby non-Hodgkin disease with 20.0 cases per 100,000. A
recent nationwide lymphoma study in Lebanon noted
an increase in lymphomas worldwide over the past decade
and argued for the need of large scale studies to assess the
increasing rates [13]. Worldwide, an annual increase of
1-2% in non-Hodgkin lymphoma incidence has been
noted, mostly in older people aged over 55 years [14].
Smoking-related cancers
Almost all smoking-related cancers in both sexes showed
a rising trend. Lung cancer showed a steeper rise in fe-
males compared to males. Tobacco smoking in Lebanon is
a major health concern; marketing of tobacco products is
permissible and smoking is an acceptable social habit.
Additionally, narguile smoking (also known as Hubble-n cancers in females (2009-2018).
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cigarette smoking is increasingly becoming more prevalent
in this population. Adult smoking is estimated at 38.5%
(males at 46% and females at 31%), and smoking among
youth shows much higher estimates (65.8% for boys and
54.1% for girls) [15]. Rates of smoking in females are con-
sidered the highest in the region and are rising at a higher
pace than those observed in neighboring countries
[16-18]. This proliferation of tobacco products and smok-
ing habits may explain the continuing rise in such
smoking-related cancers as lung and bladder cancers, in
both males and females.
Breast cancer
In Lebanon, breast cancer in females presents at a youn-
ger age, with a median of 50 years, compared to western
countries where the median age approaches 63 years
[19]. Moreover, the incidence of breast cancer among
women in general is increasing (APC = 5.4%) and is pro-
jected to continue to cause the highest morbidity burden
compared to other cancers (33%-44%). These trends can
be partly explained by widespread national breast cancer
awareness campaigns since the early 2000s, most notably
in 2003–2004, as well as the wide adoption of mammog-
raphy screening programs at reduced fees within NGOs
and primary health care centers. Awareness campaigns
increase women’s personal motivation to utilize the diag-
nostic services and sensitize physicians to suspect and
diagnose signs and symptoms of potential breast tumors
[19]. Further, significant changes in marriage and fertility
trends, with higher ages of marriage and fewer desired
children, are likely to increase the likelihood of breast
cancer incidence in the country [20]. Breast cancer is
also altered by changes in dietary habits. The nutritional
transition, characterized by an alteration in the food
choices from the traditional Mediterranean diet to a
more Westernized diet is currently underway [21,22].
National studies from Lebanon [23,24] report increasing
rates of overweight and obesity that is more evident in
females and consistent with the growing epidemic of
obesity worldwide.
Bladder cancer
We continue to observe a high incidence of bladder can-
cer relative to other cancers among males and females,
and this trend remained stable throughout the study
period. Although the incidence of bladder cancer has
been related to exposure to chlorinated water and its
byproducts and caffeine consumption [25,26], smoking
remains one of the most direct risk factors [27]. Re-
search on the higher incidence of urinary bladder cancer
in the United States and Argentina relative to Europe
and worldwide has been related to the type of curing of
the cigarettes used in these countries [28]. In particular,black tobacco (air-cured) has shown to be associated
with higher rates of urinary bladder cancer than blond
tobacco (flue-cured) [29]. In Lebanon, although the
imported cigarettes alternate between black and blond
cigarettes, the majority of the smoking population uses
black tobacco while smoking narguile. The tobacco used
for narguile smoking is locally grown and later air-cured
(oriental tobacco), and this may explain the high rates in
urinary bladder cancer in the country compared to
worldwide and regional estimates.Strengths and limitations
This study makes use of all the available six-year data to
study the direction and magnitude of the trend and pro-
ject cancer cases and incidence until 2018. The projected
estimates in this study, however, should be examined
with caution since projections assume constant inci-
dence and trend changes. Projected estimates can be
either an underestimate due to rise in known and un-
known risk factors or an overestimate due to enhanced
primary preventive efforts that might result in decrease
of cancer incidence rates. While current lifestyle-related
risk factors are not necessarily associated with increased
cancer rates due to the relatively short latency period, an
aging population and increasingly higher proportion of
elderly with higher life expectancy are consistent with
increase in the burden of cancer in the future.Conclusion
Smoking-related cancers continue to be fueled by changes
in lifestyle and the growing smoking epidemic in Lebanon,
most notably in women. Moreover, increase in life expect-
ancies and a higher proportion of older people will further
inflate cancer burden and overall incidence rates. The
health care system in Lebanon will be required to adapt to
the increasing burden of cancer in our population. The
limited resources, however, call for prioritizing prevention
and control focusing on smoking-related cancer and con-
tinue promoting early breast screening programs. Studies
are needed to examine reasons behind the notably high
incidence of bladder cancer in Lebanon.Competing interests
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